Targeted nanoagents for the detection of cancers

Molecular Oncology

Volumn 4, Issue 6, 2010, Pages 511-528

  McCarthy, Jason R ^a   Bhaumik, Jayeeta ^a   Karver, Mark R ^a   Sibel Erdem, S ^a   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Affinity ligands; Imaging; Nanomedicine

Indexed keywords

2 FLUORO 2 DEOXY DEXTRO GLUCOSE F 18; ANTIBODY; ANTIBODY CONJUGATE; APTAMER; CARBON 11; CETUXIMAB; COPPER 64; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORINE 18; GADOLINIUM; INDIUM 111; IODINE 123; IRON OXIDE; LIGAND; LIPOSOME; MONOCLONAL ANTIBODY; NANOMATERIAL; PANITUMUMAB; PEPTIDE; QUANTUM DOT; RADIOISOTOPE; TECHNETIUM 99M; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; COLON CANCER; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FLUORESCENCE IMAGING; HUMAN; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BLOCKING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE PLASMON RESONANCE; ULTRASOUND;

EID: 78349305716     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2010.08.003     Document Type: Review

References (95)

1. Aime S., Castelli D.D., Crich S.G., Gianolio E., Terreno E. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc. Chem. Res. 2009, 42:822-831.
2. American Cancer Society Cancer Facts & Figures 2009 2009, American Cancer Society, Atlanta.
3. Bagalkot V., Zhang L., Levy-Nissenbaum E., Jon S., Kantoff P.W., Langer R., Farokhzad O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano. Lett. 2007, 7:3065-3070.
4. Biju V., Mundayoor S., Omkumar R.V., Anas A., Ishikawa M. Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues. Biotechnol. Adv. 2010, 28:199-213.
5. Cairns R.A., Khokha R., Hill R.P. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr. Mol. Med. 2003, 3:659-671.
6. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 1999, 99:2293-2352.
7. Chen T.J., Cheng T.H., Chen C.Y., Hsu S.C., Cheng T.L., Liu G.C., Wang Y.M. Targeted herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J. Biol. Inorg. Chem. 2009, 14:253-260.
8. Cheng Z., Wu Y., Xiong Z., Gambhir S.S., Chen X. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug. Chem. 2005, 16:1433-1441.
9. Christiansen J.P., Lindner J.R. Molecular and cellular imaging with targeted contrast ultrasound. Proc. IEEE 2005, 93:809-818.
10. Couturier O., Luxen A., Chatal J.F., Vuillez J.P., Rigo P., Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:1182-1206.
11. Curati W.L., Halevy A., Gibson R.N., Carr D.H., Blumgart L.H., Steiner R.E. Ultrasound, CT, and MRI comparison in primary and secondary tumors of the liver. Gastrointest. Radiol. 1988, 13:123-128.
12. Dancey G., Begent R.H., Meyer T. Imaging in targeted delivery of therapy to cancer. Target. Oncol. 2009, 4:201-217.
13. Dayton P.A., Zhao S., Bloch S.H., Schumann P., Penrose K., Matsunaga T.O., Zutshi R., Doinikov A., Ferrara K.W. Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy. Mol. Imaging 2006, 5:160-174.
14. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug. Chem. 2009, 20:397-401.
15. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
16. Enochs W.S., Harsh G., Hochberg F., Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J. Magn. Reson. Imaging 1999, 9:228-232.
17. Farokhzad O.C., Karp J.M., Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv. 2006, 3:311-324.
18. Fass L. Imaging and cancer: a review. Mol. Oncol. 2008, 2:115-152.
19. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin. Exp. Metastasis 2003, 20:203-213.
20. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
21. Fisher J.L., Field C.L., Zhou H., Harris T.L., Henderson M.A., Choong P.F. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res. Treat. 2000, 61:1-12.
22. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22:969-976.
23. Graves E.E., Weissleder R., Ntziachristos V. Fluorescence molecular imaging of small animal tumor models. Curr. Mol. Med. 2004, 4:419-430.
24. Guo K.T., Paul A., Schichor C., Ziemer G., Wendel H.P. CELL-SELEX: novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci. 2008, 9:668-678.
25. Hamoudeh M., Kamleh M.A., Diab R., Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv. Drug Deliv. Rev. 2008, 60:1329-1346.
26. Han B., Nakamura M., Mori I., Nakamura Y., Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol. Rep. 2005, 14:105-112.
27. Harisinghani M.G., Weissleder R. Sensitive, noninvasive detection of lymph node metastases. PLoS Med. 2004, 1:e66.
28. Harisinghani M.G., Saini S., Weissleder R., Rubin D., deLange E., Harms S., Weinreb J., Small W., Sukerkar A., Brown J.J., Zelch J., Lucas M., Morris M., Hahn P.F. Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations. J. Comput. Assist. Tomogr. 2001, 25:770-776.
29. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., de la Rosette J., Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 2003, 348:2491-2499.
30. Harrington K.J., Mohammadtaghi S., Uster P.S., Glass D., Peters A.M., Vile R.G., Stewart J.S. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 2001, 7:243-254.
31. Herbst R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:21-26.
32. Hilderbrand S.A., Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr. Opin. Chem. Biol. 2010, 14:71-79.
33. Hoffman R.M. Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin. Exp. Metastasis 2009, 26:345-355.
34. Hornak J.P. The basics of MRI http://www.cis.rit.edu/htbooks/mri/.
35. Hung M.C., Lau Y.K. Basic science of HER-2/neu: a review. Semin. Oncol. 1999, 26:51-59.
36. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
37. Jensen J.A. Medical ultrasound imaging. Prog. Biophys. Mol. Biol. 2007, 93:153-165.
38. Jiang S., Gnanasammandhan M.K., Zhang Y. Optical imaging-guided cancer therapy with fluorescent nanoparticles. J. R Soc. Interface 2010, 7:3-18.
39. Jobsis F.F. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science 1977, 198:1264-1267.
40. Kaneda M.M., Caruthers S., Lanza G.M., Wickline S.A. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann. Biomed. Eng. 2009, 37:1922-1933.
41. Kaufmann B.A., Lindner J.R. Molecular imaging with targeted contrast ultrasound. Curr. Opin. Biotechnol. 2007, 18:11-16.
42. Kelly K.A., Setlur S.R., Ross R., Anbazhagan R., Waterman P., Rubin M.A., Weissleder R. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res. 2008, 68:2286-2291.
43. Kherlopian A.R., Song T., Duan Q., Neimark M.A., Po M.J., Gohagan J.K., Laine A.F. A review of imaging techniques for systems biology. BMC Syst. Biol. 2008, 2:74.
44. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J. Clin. 1999, 49:8-31. 1.
45. Lanza G.M., Winter P.M., Caruthers S.D., Hughes M.S., Cyrus T., Marsh J.N., Neubauer A.M., Partlow K.C., Wickline S.A. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine 2006, 1:321-329.
46. Lee H.Y., Li Z., Chen K., Hsu A.R., Xu C., Xie J., Sun S., Chen X. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med. 2008, 49:1371-1379.
47. Levy-Nissenbaum E., Radovic-Moreno A.F., Wang A.Z., Langer R., Farokhzad O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008, 26:442-449.
48. Li X., Du X., Huo T., Liu X., Zhang S., Yuan F. Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner. Acta Radiol. 2009, 50:583-594.
49. Lin M.M., Kim do K., El Haj A.J., Dobson J. Development of superparamagnetic iron oxide nanoparticles (SPIONS) for translation to clinical applications. IEEE Trans. Nanobioscience 2008, 7:298-305.
50. Lin W., Hyeon T., Lanza G.M., Zhang M., Meade T.J. Magnetic nanoparticles for early detection of cancer by magnetic resonance imaging. MRS Bull. 2009, 34:441-448.
51. Low P.S., Kularatne S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 2009, 13:256-262.
52. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
53. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 2000, 65:271-284.
54. Mardirossian G., Brill A.B., Dwyer K.M., Kahn D., Nelp W. Radiation absorbed dose from indium-111-CYT-356. J. Nucl. Med. 1996, 37:1583-1588.
55. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
56. Maurer A.H. Combined imaging modalities: PET/CT and SPECT/CT. Health Phys. 2008, 95:571-576.
57. McCarthy J.R., Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 2008, 60:1241-1251.
58. McCarthy J.R., Kelly K.A., Sun E.Y., Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine (Lond) 2007, 2:153-167.
59. Meng J., Fan J., Galina G., Branca R.T., Clasen P.L., Ma S., Zhou J., Leuschner C., Kumar C.S.R.R., Hormes J., Otiti T., Beye A.C., Harmer M.P., Kiely C.J., Warren W., Haataja M.P., Soboyejo W.O. LHRH-functionalized supermagnetic iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI. Mater. Sci. Eng. C 2009, 29:1467-1479.
60. Mittelstaedt C.A. Ultrasound as a useful imaging modality for tumor detection and staging. Cancer Res. 1980, 40:3072-3078.
61. Montet X., Weissleder R., Josephson L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug. Chem. 2006, 17:905-911.
62. Moore G.E., Peyton W.T., et al. The clinical use of fluorescein in neurosurgery; the localization of brain tumors. J. Neurosurg. 1948, 5:392-398.
63. Mulder W.J., Strijkers G.J., Habets J.W., Bleeker E.J., van der Schaft D.W., Storm G., Koning G.A., Griffioen A.W., Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005, 19:2008-2010.
64. Nahrendorf M., Waterman P., Thurber G., Groves K., Rajopadhye M., Panizzi P., Marinelli B., Aikawa E., Pittet M.J., Swirski F.K., Weissleder R. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1444-1451.
65. Ntziachristos V. Fluorescence molecular imaging. Annu. Rev. Biomed. Eng. 2006, 8:1-33.
66. Park J.H., von Maltzahn G., Ruoslahti E., Bhatia S.N., Sailor M.J. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew. Chem. Int. Ed. Engl. 2008, 47:7284-7288.
67. Phillips W.T. Delivery of gamma-imaging agents by liposomes. Adv. Drug Deliv. Rev. 1999, 37:13-32.
68. Rapoport N., Gao Z., Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl. Cancer Inst. 2007, 99:1095-1106.
69. Retel V.P., Hummel M.J., van Harten W.H. Review on early technology assessments of nanotechnologies in oncology. Mol. Oncol. 2009, 3:394-401.
70. Saini S., Stark D.D., Hahn P.F., Bousquet J.C., Introcasso J., Wittenberg J., Brady T.J., Ferrucci J.T.J. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 1987, 162:217-222.
71. Saini S., Sharma R., Baron R.L., Turner D.A., Ros P.R., Hahn P.F., Small W.C., Delange E.E., Stillman A.E., Edelman R.R., Runge V.M., Outwater E.K. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Clin. Radiol. 2000, 55:690-695.
72. Saltz L., Easley C., Kirkpatrick P. Panitumumab. Nat. Rev. Drug Discov. 2006, 5:987-988.
73. Sampath L., Kwon S., Ke S., Wang W., Schiff R., Mawad M.E., Sevick-Muraca E.M. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J. Nucl. Med. 2007, 48:1501-1510.
74. Santra S., Dutta D., Walter G.A., Moudgil B.M. Fluorescent nanoparticle probes for cancer imaging. Technol. Cancer Res. Treat. 2005, 4:593-602.
75. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., Derfus A.M., Yang M., Hoffman R.M., Bhatia S., Sailor M.J., Ruoslahti E. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. U.S.A 2007, 104:932-936.
76. Stark D.D., Moseley M.E., Bacon B.R., Moss A.A., Goldberg H.I., Bass N.M., James T.L. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1985, 154:137-142.
77. Stephenson A.J., Eastham J.A. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J. Clin. Oncol. 2005, 23:8198-8203.
78. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco F.J.J., Dotan Z.A., Fearn P.A., Kattan M.W. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl. Cancer Inst. 2006, 98:715-717.
79. Tang Y., Kim M., Carrasco D., Kung A.L., Chin L., Weissleder R. In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. Cancer Res. 2005, 65:8324-8330.
80. Tassa C., Duffner J.L., Lewis T.A., Weissleder R., Schreiber S.L., Koehler A.N., Shaw S.Y. Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug. Chem. 2010, 21:14-19.
81. Ting G., Chang C.H., Wang H.E. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res. 2009, 29:4107-4118.
82. Tran T., Engfeldt T., Orlova A., Sandstrom M., Feldwisch J., Abrahmsen L., Wennborg A., Tolmachev V., Karlstrom A.E. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug. Chem. 2007, 18:1956-1964.
83. Tran T.D., Caruthers S.D., Hughes M., Marsh J.N., Cyrus T., Winter P.M., Neubauer A.M., Wickline S.A., Lanza G.M. Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int. J. Nanomedicine 2007, 2:515-526.
84. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
85. Wang K., Wang K., Li W., Huang T., Li R., Wang D., Shen B., Chen X. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol. 2009, 50:1095-1103.
86. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
87. Weissleder R., Hahn P.F., Stark D.D., Rummeny E., Saini S., Wittenberg J., Ferrucci J.T. MR imaging of splenic metastases: ferrite-enhanced detection in rats. AJR Am. J. Roentgenol. 1987, 149:723-726.
88. Weissleder R., Stark D.D., Compton C.C., Wittenberg J., Ferrucci J.T. Ferrite-enhanced MR imaging of hepatic lymphoma: an experimental study in rats. AJR Am. J. Roentgenol 1987, 149:1161-1165.
89. Weissleder R., Kelly K., Sun E.Y., Shtatland T., Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 2005, 23:1418-1423.
90. Xing Y., Rao J. Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomark. 2008, 4:307-319.
91. Yang L., Mao H., Wang Y.A., Cao Z., Peng X., Wang X., Duan H., Ni C., Yuan Q., Adams G., Smith M.Q., Wood W.C., Gao X., Nie S. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009, 5:235-243.
92. Yang L., Peng X.H., Wang Y.A., Wang X., Cao Z., Ni C., Karna P., Zhang X., Wood W.C., Gao X., Nie S., Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 2009, 15:4722-4732.
93. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
94. Zhang D., Feng X.Y., Henning T.D., Wen L., Lu W.Y., Pan H., Wu X., Zou L.G. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur. J. Radiol. 2009, 70:180-189.
95. Zhang H., Ma Y., Sun X.L. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med. Res. Rev. 2010, 30:270-289.